KLRS · Kalaris Therapeutics, Inc.
$4.10
+0.02 (+0.49%)
At close · Aug 27
Market Cap
$99.98M
Shares
23.80M
Income-statement, balance-sheet and cash-flow figures extracted from the company's SEC filings — 10-K annual and 10-Q quarterly reports — and standardised for comparison across periods.
Revenue
$165K
FY2019
Net Income
-$43.44M
+37.2%
FY2025
Operating Margin
-16182.42%
FY2019
Diluted EPS
-$2.85
+94.5%
FY2025
Operating Cash Flow
-$38.37M
-85.6%
FY2025
Chart any reported metric, KPI or segment over time — the full statement history lives here
Search above to add metrics — fundamentals, product and segment revenue, company KPIs, valuation.
| Line Item | TTM | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 | FY2020 | FY2019 |
|---|---|---|---|---|---|---|---|---|
| — | — | — | — | — | — | — | $165K | |
| $32.87M | $30.75M | $45.04M | $133.07M | $118.87M | $120.74M | $49.66M | $16.25M | |
| $14.89M | $15.4M | $6.69M | $48.26M | $52.33M | $49.08M | $21.65M | $10.62M | |
| — | — | — | $398K | $723K | $189K | $73K | $19K | |
| — | — | $10.19M | — | — | — | — | — | |
| $47.76M | $46.15M | $51.73M | $199.9M | $171.2M | $169.82M | $71.31M | $26.87M | |
| -$47.76M | -$46.15M | -$51.73M | -$199.9M | -$171.2M | -$169.82M | -$71.31M | -$26.7M | |
| — | — | — | — | — | — | — | -16182.42% | |
| — | — | — | -$199.5M | -$170.48M | -$169.63M | -$71.24M | -$26.68M | |
| $0 | $1.44M | $2.7M | — | — | — | — | — | |
| — | — | $5.49M | $5.73M | $1.88M | $1.32M | $1.33M | $2.07M | |
| $3.5M | $2.71M | -$17.44M | $3.62M | $351K | -$2.45M | $195K | $797K | |
| — | -$43.44M | -$69.17M | -$190.54M | -$168.98M | -$170.96M | -$69.78M | -$23.84M | |
| — | $0 | $0 | -$126K | -$265K | $1.01M | — | — | |
| -$44.26M | -$43.44M | -$69.17M | -$190.42M | -$168.71M | -$171.96M | -$69.78M | -$23.84M | |
| — | — | — | — | — | — | — | -14447.88% | |
| -$44.34M | -$43.43M | -$69.17M | -$190.01M | -$169.02M | -$172.01M | -$69.96M | -$23.77M | |
| USD/shares | -$0.66 | -$2.85 | -$51.77 | -$42.09 | -$50.60 | -$63.02 | — | — |
| USD/shares | -$0.66 | -$2.85 | -$51.77 | -$42.09 | -$50.60 | -$63.02 | — | — |
| shares | — | 15.27M | 1.34M | 4.52M | 3.33M | 2.73M | 1.17M | 55.91K |
| shares | — | 15.27M | 1.34M | 4.52M | 3.33M | 2.73M | 1.17M | 55.91K |
Italic rows are computed from reported lines — open a row's info icon for its formula. Values reflect the latest filing (restatements included); per-share figures on today's split basis. Click a value for its source filing.
TTM: trailing twelve months through the latest reported quarter — flows sum the last four quarters, balances take the latest. 3Y/5Y/10Y columns are trailing CAGR from the newest fiscal year; blank where an endpoint is missing or negative.
Price & Valuation
Multiples computed on the strict TTM/EV methodology — today's snapshot against peers, and each ratio recomputed as of past filing dates.
Valuation
EV/Revenue
—
Peer median 4.12×
EV/EBIT
—
Peer median 11.76×
P/E (TTM)
—
Peer median 10.33×
Peer medians compare against the 296 similar-size Biotechnology companies (of 517 listed).
Key facts
CIK
1754068
CUSIP
482929106
13F (30d)
55 filings
55 filers
Visit website
Investor relations